ImageneBio Inc (IMA) Stock Analysis & Investment Frameworks
ImageneBio Inc (IMA) stock analysis on Invetso. Review ImageneBio Inc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
ImageneBio Inc Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
ImageneBio Inc Key Financial Metrics
- Market Cap: $45.86M
- Revenue: $800000.00
- ROE: -38.99%
- ROIC: -39.76%
- Dividend Yield: N/A
About ImageneBio Inc
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio Inc Investment Frameworks
Invetso analyzes ImageneBio Inc (IMA) across the following frameworks:
- ImageneBio Inc 10Y Growth Potential
- ImageneBio Inc Scenario Analysis
- ImageneBio Inc Risks & Opportunities
- ImageneBio Inc Economic Moat
- ImageneBio Inc Business Model
- ImageneBio Inc Management
- ImageneBio Inc SWOT Analysis
- ImageneBio Inc Porter's 5 Forces
- ImageneBio Inc PESTLE Analysis
- ImageneBio Inc ESG Analysis